Spotlight Pathology Ltd - Filleted accounts

Registered number

12435884

Spotlight Pathology Ltd

Unaudited Filleted Accounts

31 January 2026

Spotlight Pathology Ltd
Registered number:		12435884
Directors' Report



The directors present their report and accounts for the year ended 31 January 2026.

Spotlight Pathology had another transformational year. Spotlight raised additional equity funding and achieved a number of key milestones namely passing ISO 13485 initial audits, gaining UKCA certification of Spotlight Lymphoma, and submitting the Spotlight Lymphoma IVDR submission in early 2026. The regulatory achievements have enabled Spotlight to first clinical pilot studies of the Spotlight Lymphoma device, due to commence in early 2026.

Spotlight Pathology continues to work on the development of follow-on pathology diagnostic products to expand the product portfolio, with additional products expected to reach commercial readiness by Q4 2026. Non-UK engagements will commence in 2026 along with expansion of UK sales. To achieve this, Spotlight plans to expand the technical and commercial teams between 2026 and 2027.

The team at Spotlight are looking forward to growth and expansion in 2026, building upon the strong company foundations that have been established throughout 2025.



Principal activities
The company's principal activity during the period was business and domestic software development.

Directors
The following persons served as directors during the year:

	M P Fergie
	Dr R J Byers
	Dr A E Round
	S J Perona
	M Gehrung

Small company provisions
This report has been prepared in accordance with the provisions in Part 15 of the Companies Act 2006 applicable to companies subject to the small companies regime.

This report was approved by the board on 3 July 2026 and signed on its behalf.





S J Perona
Director

Spotlight Pathology Ltd
Registered number:			12435884
Balance Sheet
as at 31 January 2026



Notes			2026			2025
£			£	£		£
Fixed assets
Tangible assets	3		3,027			3,805

Current assets
Debtors	4	122,188			29,205
Cash at bank and in hand		520,795			114,648
		642,983			143,853

Creditors: amounts falling due within one year	5	(94,788)			(148,512)

Net current assets/(liabilities)			548,195			(4,659)

Net assets/(liabilities)			551,222			(854)

Capital and reserves
Called up share capital			180			120
Share premium			1,350,378			335,006
Profit and loss account			(799,336)			(335,980)

Shareholders' funds			551,222			(854)


The directors are satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006.
The members have not required the company to obtain an audit in accordance with section 476 of the Act.
The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
The accounts have been prepared and delivered in accordance with the special provisions applicable to companies subject to the small companies regime. The profit and loss account has not been delivered to the Registrar of Companies.




S J Perona
Director
Approved by the board on 3 July 2026

Spotlight Pathology Ltd
Notes to the Accounts
for the year ended 31 January 2026


1	Accounting policies

	Basis of preparation
	The accounts have been prepared under the historical cost convention and in accordance with FRS 102, The Financial Reporting Standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).

	Turnover
	Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.

	Going concern
	The directors have prepared forecasts for a minimum of 12 months. The company may require further capitalisation by the end of 2026. Existing shareholders have indicated willingness to invest further, and there are promising ongoing discussions with several potential new investors. Sufficient investment funding is therefore expected during 2026 to fund the company for the next 12 months.

	Tangible fixed assets
	Tangible fixed assets are measured at cost less accumulative depreciation and any accumulative impairment losses. Depreciation is provided on all tangible fixed assets, other than freehold land, at rates calculated to write off the cost, less estimated residual value, of each asset evenly over its expected useful life, as follows:

	Equipment	over 3 years

	Debtors
	Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.

	Creditors
	Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.

	Taxation
	A current tax liability is recognised for the tax payable on the taxable profit of the current and past periods. A current tax asset is recognised in respect of a tax loss that can be carried back to recover tax paid in a previous period. Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference, except for revalued land and investment property where the tax rate that applies to the sale of the asset is used. Current and deferred tax assets and liabilities are not discounted.







	Pensions
	Contributions to defined contribution plans are expensed in the period to which they relate.



2	Employees		2026		2025
Number				Number

	Average number of persons employed by the company		5		4



3	Tangible fixed assets
					Equipment
£
	Cost
	At 1 February 2025				8,344
	Additions				1,698
	At 31 January 2026				10,042

	Depreciation
	At 1 February 2025				4,539
	Charge for the year				2,476
	At 31 January 2026				7,015

	Net book value
	At 31 January 2026				3,027
	At 31 January 2025				3,805




4	Debtors		2026		2025
£				£

	Other debtors		122,188		29,205



5	Creditors: amounts falling due within one year		2026		2025
£				£

	Trade creditors		60,467		6,659
	Taxation and social security costs		15,042		7,771
	Accruals		19,279		6,300
	Loan		-		125,000
	Other creditors		-		2,782
			94,788		148,512










6	Other information

	Spotlight Pathology Ltd is a private company limited by shares and incorporated in England. Its registered office is:
	The Innovation Centre
	Sci-Tech Daresbury Keckwick Lane
	Daresbury
	Warrington
	WA4 4FS